Trial · NCT02558400

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02558400, Phase 3, Completed, Aerie Pharmaceuticals; results first posted 2019-06-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension. Trials, record NCT02558400. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02558400

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
NCT number: NCT02558400
Status: Completed
Phases: Phase 3
Enrollment: 718 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: PG324 Ophthalmic Solution 0.02%/0.005%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%, Latanoprost Ophthalmic Solution 0.005%
First posted: 2015-09-24
Last updated: 2019-06-04
Results first posted: 2019-06-04

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)	The primary efficacy variable was mean IOP at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90, as measured by Goldmann applanation tonometry. Secondary analysis were conducted as a part of safety measurements to month 12 on treatment.
Secondary	Extent of Exposure	12 months	Exposure to study medication in days for all treatment groups

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	Primary efficacy endpoint measured for 3 months (data collected at 08:00, 10:00 and 16:00 hours at Day 15, Day 43 and Day 90)	Intent to Treat (ITT) population	mmHg	MEAN
SECONDARY	Extent of Exposure	12 months	The safety population= all randomized subjects who received at least 1 dose of study medication. The safety population summarized subjects as-treated. 1 Subject was randomized to netarsudil but received latanoprost. Therefore, 1 less subject is in the netarsudil group and 1 additional subject is in the latanoprost group for the safety population.	days	MEAN

Source ClinicalTrials.gov

Results by group39

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 0800 hours	24.84	Standard Deviation 3.316	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02%	Day 1, 0800 hours	24.81	Standard Deviation 3.335	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 0800 hours	24.59	Standard Deviation 2.914	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 1000 hours	23.72	Standard Deviation 3.587	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02%	Day 1, 1000 hours	23.45	Standard Deviation 3.510	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 1000 hours	23.43	Standard Deviation 3.385	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 1, 1600 hours	22.59	Standard Deviation 3.610	mmHg
Intraocular Pressure (IOP)	AR-13324 Ophthalmic Solution 0.02%	Day 1, 1600 hours	22.63	Standard Deviation 3.674	mmHg
Intraocular Pressure (IOP)	Latanoprost Ophthalmic Solution 0.005%	Day 1, 1600 hours	23.43	Standard Deviation 3.370	mmHg
Intraocular Pressure (IOP)	PG324 Ophthalmic Solution	Day 15, 0800 hours	15.68	Standard Deviation 3.532	mmHg

1 to 10 of 39Source ClinicalTrials.gov

See all 39 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	PG324 Ophthalmic Solution 0.02%/0.005%	238
Overall Study	STARTED	AR-13324 Ophthalmic Solution 0.02%	244
Overall Study	STARTED	Latanoprost Ophthalmic Solution 0.005%	236
Overall Study	COMPLETED	PG324 Ophthalmic Solution 0.02%/0.005%	159
Overall Study	COMPLETED	AR-13324 Ophthalmic Solution 0.02%	148
Overall Study	COMPLETED	Latanoprost Ophthalmic Solution 0.005%	203
Overall Study	NOT COMPLETED	PG324 Ophthalmic Solution 0.02%/0.005%	79
Overall Study	NOT COMPLETED	AR-13324 Ophthalmic Solution 0.02%	96
Overall Study	NOT COMPLETED	Latanoprost Ophthalmic Solution 0.005%	33

Source ClinicalTrials.gov

Adverse events114

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Conjunctival Hyperaemia	Eye disorders	PG324 Ophthalmic Solution	133	238	133
other	Conjunctival Hyperaemia	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	115	243	115
other	Conjunctival Hyperaemia	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	44	237	44
other	Cornea Verticillata	Eye disorders	PG324 Ophthalmic Solution	39	238	39
other	Cornea Verticillata	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	32	243	32
other	Cornea Verticillata	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	0	237	0
other	Eye Pruritus	Eye disorders	PG324 Ophthalmic Solution	20	238	20
other	Eye Pruritus	Eye disorders	AR-13324 Ophthalmic Solution 0.02%	20	243	20
other	Eye Pruritus	Eye disorders	Latanoprost Ophthalmic Solution 0.005%	2	237	2
other	Lacrimation Increased	Eye disorders	PG324 Ophthalmic Solution	15	238	15

1 to 10 of 114Source ClinicalTrials.gov

See all 114 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	PG324 Ophthalmic Solution	0	238
Total, all-cause mortality	AR-13324 Ophthalmic Solution 0.02%	1	243
Total, all-cause mortality	Latanoprost Ophthalmic Solution 0.005%	0	237
Total, other adverse events	PG324 Ophthalmic Solution	169	238
Total, other adverse events	AR-13324 Ophthalmic Solution 0.02%	160	243
Total, other adverse events	Latanoprost Ophthalmic Solution 0.005%	74	237
Total, serious adverse events	PG324 Ophthalmic Solution	5	238
Total, serious adverse events	AR-13324 Ophthalmic Solution 0.02%	10	243
Total, serious adverse events	Latanoprost Ophthalmic Solution 0.005%	10	237

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
32166538	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02558400

GET https://conductscience.org/api/trials/v1/NCT02558400/results?page=2

API reference For AI assistants